Without a precise and accurate definition, we may never find a cure.
The signature case of Alzheimers disease was a German woman named Auguste whose mental status began to deteriorate to the extent that her husband brought her to a psychiatry clinic in Frankfurt. As is traditional, the scientific literature until very recently referred to Auguste merely by her first name plus the initial of her last name Auguste D. She was seen at the Frankfurt psychiatric hospital in 1901, and her attending physician at the time was a young 30-something anatomist turned psychiatrist, Alois Alzheimer. Alzheimer came to this case from early interests in the structure of the brain, basically its anatomy and cellular structure. This very structure-based view of brain function was the context he brought to his clinical experiences in psychiatry, a craft he learned under the guidance of Dr. Emil Sioli in Frankfurt-am-Main.
In April 1906, his old mentor Dr. Sioli sent word to Alzheimer that Auguste D. had died. Alzheimer was pleased to learn that Sioli had arranged for an autopsy and had sent tissue from the brain of the deceased woman to Munich for Alzheimer to examine.
Two features of the preparation in particular caught his eye. The first he described in this way: Throughout the whole cortex one finds miliar foci, which are caused by deposition of a peculiar substance in the cortex. The peculiar substance we now know was a waxy form of aggregated protein known as amyloid. The depositions would come to be known as amyloid plaques. The second feature he described thusly: very peculiar changes in the neurofibrils only a tangle of fibrils indicates where a nerve cell had been previously located. These peculiar neurofibrils are actually aggregates of a different protein known as tau. We now refer to these aggregates as neurofibrillary tangles.
In this way the odd deposits now known as plaques and tangles became tightly linked to a specific form of dementia. Alzheimer made detailed notes on his discovery and took them to his superior, Emil Kraepelin. He was quite certain that the plaques and tangles were the explanation for the highly unusual behavior of Auguste D. Kraepelin apparently liked the idea enough that he suggested that Alzheimer present his findings at a meeting of German psychiatrists in the fall of 1906. Alzheimer agreed and went to Tbingen that fall to announce his discovery.
The original observation was an important case study, but it was elevated to the level of a disease for reasons that were strategic, not scientific.
The story might have ended here as a long-forgotten case study gathering dust in the archives of medicine. Alzheimers boss Kraepelin, however, had other ideas. He too was a believer in the idea that psychiatric disease was caused by changes in the physical structure of the brain. The novel plaques and tangles that Alzheimer had found in the brain of Auguste D. neatly fit that philosophy. Kraepelin was very well-known at the time, in part because he was the author of a widely used textbook, Psychiatrie. Kraepelin would periodically update his textbook to include the latest findings (and maybe to sell more books), and, as luck would have it, at the time that Alzheimer published his case, Kraepelin was preparing the eighth edition. To add more support to his own philosophy of the brain, he decided to include the case of Auguste D. in his revision. One might imagine it felt awkward to include a simple case study in a widely used textbook. Kraepelin cleverly solved this problem by elevating the case of Auguste D. to the status of a disease. He called it Alzheimers disease, and he included this new condition in the 1910 edition of Psychiatrie.
This was a bold and almost reckless move that, in retrospect, had a huge and outsized influence on the field. In most cases, I like it when scientists are bold. Put up a clever argument, and let a smart and informed debate refine it or rebuke it. Either way, science advances. Reckless is not so good. A textbook paragraph is much weightier than the same paragraph in a journal article or a meeting presentation. Textbooks impart a feeling of permanence to an entry. Their contents are imbued with the unspoken assertion that they represent settled art and thus are not easily questioned. Putting Augustes condition in a textbook as a new disease comes pretty close to reckless because, on the flimsiest of grounds, Kraepelin was trying to put the Case Closed stamp on this telling of what he called Alzheimers disease. It was to be the first of three inflations in the definition of Alzheimers disease.
Lets go back and consider Alzheimers findings in the brain of Auguste D. Two unusual features occurred together. Unusual deposits, plaques and tangles, were correlated with a highly unusual dementia. One possibility to explain the presence of plaques and tangles in the brain of a person with dementia is the one Alzheimer and Kraepelin favored: The plaques and tangles caused the dementia. That fit well with their philosophies that the function of the brain was governed largely by its structure. It most likely explains why Alzheimer championed this first explanation and why Kraepelin was so eager to promote it. But perhaps Auguste D.s peculiar dementia caused the brain changes that led to plaques and tangles. The plaques didnt cause the disease; the disease caused the plaques.
Ive told the story of Alzheimer and Auguste D. in great detail because it tells us a lot about why the field is stuck and why a successful treatment for Alzheimers has been so slow in coming. The original observation was an important case study, but it was elevated to the level of a disease for reasons that were strategic, not scientific. Both Kraepelin and Alzheimer were subscribers to a school of thought that held that the structure of the brain was the key to its function, and that if the structure became littered with abnormal deposits, its function would also become abnormal. Finding plaques and tangles in the brain of a person with dementia fit that idea, and putting it forward as a hypothesis was reasonable. From these origins, however, the two psychiatrists inadvertently biased the thinking of subsequent generations of physicians and scientists. Their assertion that the correlation of plaques and dementia represented a causal relationship plaques caused the dementia has proven very hard to shake off, despite the shortage of evidence to support it.
For Alzheimer and Kraepelin, the rare form of early-onset dementia they named Alzheimers disease was, they believed, caused by the deposits they had seen in the brain of Auguste D. That first linkage of deposits and dementia was the Trojan horse that released the soldiers of the second inflation. Published in 1976, the article most commonly cited as the manifesto of this effort was written by Robert Katzman and bore the fearsome title Editorial: The Prevalence and Malignancy of Alzheimer Disease: A Major Killer. Katzman began his two-page editorial by arguing that there was no really significant difference between the relatively rare condition that was known at the time as Alzheimers disease and the far more common condition known as senile dementia. He then went on to argue that dementia was badly underdiagnosed as a cause of death. He estimated that if the cause of death were adjusted to honestly reflect this fact, dementia was arguably a major killer. The real purpose of the editorial, however, was to argue for equating senile dementia with Alzheimers disease. This was a bit of a stretch.
To bolster his case for their equivalence, Katzman cited earlier clinical speculation that Alzheimers disease and senile dementia were similar in their symptoms. He also cited a pair of papers published a few years earlier. Katzman wrote, based on his analysis of these two papers, that when comparing the microscopic appearance of the brain of a person who had died with Alzheimers disease with one who had died with the more common senile dementia, The pathological findings are identical atrophy of the brain, marked loss of neurons, neurofibrillary tangles, granulovacuolar changes, and neuritic (senile) plaques.
The problem is that this is not exactly what the two papers had claimed. In fact, five cases with clinical dementia (10 percent of the authors subjects) could not be diagnosed with confidence by the microscopic appearance of the brain, and 40 percent had changes that would have led to a non-Alzheimers diagnosis. In the end, only 50% were considered to be cases of senile dementia showing the histological features of Alzheimers disease. This is hardly a rock on which to build the claim that senile dementia and Alzheimers disease are one and the same.
Katzmans inflated view of Alzheimers disease, however, soon took hold. By 1980, it had earned a place in the third edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-III). Subsequently, attempts were made to precisely define the pathology needed for a diagnosis of Alzheimers disease. Eventually, there were so many authoritative sources on how to diagnose Alzheimers disease that a well-meaning clinician could surely have been forgiven for getting frustrated about what this newly inflated condition really was and whether it applied to the elderly person sitting in his or her office.
To attempt to deal with this, a working group was assembled under the auspices of the National Institute on Aging (NIA) and the Alzheimers Association (then known as the Alzheimers Disease and Related Disorders Association ADRDA) to formalize the clinical diagnosis of Alzheimers disease. The working group came up with a list of criteria to diagnose what they called PROBABLE Alzheimers Disease [all caps is their emphasis]. But the group went one step further. They established criteria for a diagnosis of DEFINITE Alzheimers disease. For this score, you first had to have a clinical diagnosis of dementia, using the following five criteria: dementia established by clinical examination; deficits in two or more areas of cognition (problem solving, language, attention, etc.); progressive worsening; no disturbance of consciousness; and onset between ages 40 and 90, most often after age 65. But you also needed histopathologic [i.e., microscopic] evidence obtained from a biopsy or autopsy. And what did they consider definitive histopathologic evidence? Remarkably, they didnt say. Our well-meaning clinician had to wait until the following year when a separate summary of the workshop was published.
The details are important to the aficionado, but its the big picture that is important to us. Alzheimers disease was to be defined by the presence of plaques. Yet plaques are a feature that is not present in 15 percent of the people with a clinical diagnosis of Alzheimers, and a feature that is present in people of all ages including 30 percent of elderly people without any cognitive impairment. If this doesnt make sense to you, its because it doesnt make sense.
Alzheimers disease is defined by the presence of plaques, a feature that is present in people of all ages, including 30 percent of elderly people without any cognitive impairment.
So, who died and made the pathologist king? There was really no good reason for pathology to trump neurology. You can get a definitive diagnosis of any number of complex brain diseases autism, depression, schizophrenia, epilepsy, and many others without any pathological study or live imaging of the brain. If a child psychiatrist diagnoses a young boy as having autism, there is no need for a brain scan to test the psychiatrists skill. For the purposes of treatment, the child has autism. If a neurologist diagnoses a person as having Parkinsons, thats the diagnosis. They dont wait with bated breath to find out whether there were -synuclein deposits in the brain. For the purposes of treatment, the person has Parkinsons disease. Late-life diseases like Parkinsons and Huntingtons do have characteristic brain abnormalities, but it is the presentation of the clinical symptoms that allows physicians to have confidence in their diagnosis. To be fair, if an autopsy is done and there are no deposits, the diagnosis is questioned, but not rejected. The clinical diagnosis overrules the pathology. As it should.
Then our clinical trials started failing, our antibody trials in particular. In the basic research laboratories of the world, data kept accumulating that violated the expectations of an amyloid-only definition for Alzheimers disease biology. In response the NIA began to recognize that there was a broad consensus that the criteria should be revised to incorporate state-of-the-art scientific knowledge. The result was a truly comprehensive review a compendium of four papers comprising reports of three working groups plus an introductory summary. Coming as it did, a full quarter century after the Consortium to Establish a Registry for Alzheimers Disease (CERAD) working group met, it would have been an ideal platform to announce the decision to cut the definition of Alzheimers disease loose from the presence of plaques. Instead the experts in the field doubled down and bet the store on amyloid. In doing so, they made the entire situation much, much worse.
Writing the first paper was a clear struggle for its authors. The task before the group was to come up with a recommendation for how practicing physicians should decide whether or not a living person, sitting in front of them in their office, had Alzheimers disease. But reading their words, it is quite clear they were not about to be drawn into saying in print that amyloid, or any other biomarker (like tau), should be used to define Alzheimers disease. They made a clean and explicit separation between a clinical diagnosis of Alzheimers disease dementia and what they called the pathophysiological process of Alzheimers disease. What the group essentially said was that in the clinic the presence or absence of amyloid is just a piece of information that can be helpful in reaching a diagnosis, and nothing more.
The second paper in the series was important for the attempt of the working group to define what is known as MCI (mild cognitive impairment). The goal was a useful one: to try to clinically identify Alzheimers disease as early as possible so that treatment could begin when the probability for meaningful impact was the greatest. These authors were a separate group of neurologists. They too wrestled with how to incorporate biomarkers into their recommendations. In the end, they conclude, Considerable work is needed to validate the criteria that use biomarkers and to standardize biomarker analysis for use in community settings. Like the clinicians in the first paper, they are willing to say that people who have no evidence of amyloid or tau are unlikely to have MCI due to Alzheimers disease, but they add the caveat that such individuals may still have AD, [but for these patients] a search for an alternate cause of the MCI syndrome is warranted. As with the first group, the MCI paper is arguing that while evidence of amyloid and tau may be useful information, it is not definitive.
The first two papers had basically said that pathology was only one of several things to consider in reaching a diagnosis. The third paper in the series, however, put the pathophysiology front and center in our definition of Alzheimers disease. More than that, however, it exploded our definition of Alzheimers disease almost beyond recognition. This is the third inflationary event in the history of Alzheimers disease, and unfortunately, compared to the expansions ushered in by Kraepelin and later by Katzman, this third inflation was bigger and more destructive to the field.
It wreaked havoc by redefining the earliest stages of Alzheimers disease. This redefinition created what was in effect a totally new stage of the disease process: preclinical Alzheimers disease. By preclinical the authors meant that people with plaques in their brain (or the wrong amount of amyloid in their cerebrospinal fluid) are not healthy people. They already have Alzheimers disease. They just havent started to show the symptoms yet. In this telling of the story, the 30 percent of elderly people who have plaques but also have normal brain function are not simply healthy people with plaques. They are sick people without symptoms.
This may seem to be just semantics, but its actually an incredibly audacious claim. About 1 in every 10 people over the age of 65 have some symptoms of Alzheimers disease. Thats 10 percent of the elderly. The other 90 percent have normal, age-appropriate brain function. But weve already learned that about a third of the people in this cognitively normal group have significant levels of plaques in their brain. Therefore, according to this new expanded definition, they have preclinical Alzheimers disease. The authors are essentially arguing that we should increase our estimates of the total number of cases of Alzheimers disease by threefold. Worse still, the authors are making this recommendation despite the fact that there are reasonable doubts as to whether or not amyloid causes Alzheimers disease. Ah, you may say, but arent those doubts just the rantings of a few crazed misfits at the fringes of the field? Not really. We just read about these same doubts in the first two papers in the series.
The authors of the third paper understood that they were redefining Alzheimers disease, and they were clearly conflicted about what they were doing. In the final paragraph they admit, The definitive studies are likely to take more than a decade to fully accomplish. Said in plain language, we have this idea, but we dont have the data to back it up. Still, we are going to go with our gut, upend both basic and clinical research, and youre going to have to live with it because most of your grant money comes from the NIA and the Alzheimers Association and their names are on this paper.
This is a huge problem because the definition of a disease is one of its most important attributes. Without a precise and accurate definition, there is no way to find a cure for any disease. Sadly, throughout the long history of Alzheimers disease research, strategy and politics have overruled science in the push to apply the label of Alzheimers disease to an ever-larger fraction of age-related cognitive decline and aging. As a result, we are left with basically no definition or at least none of any value. Being in this situation, we are effectively blocked from making any real progress toward treatment. For proof of this, one needs to look no further than the unbroken string of expensive clinical trial failures. Our political calculus has overruled our common sense and caused us to stop listening to our own data a clear example of how not to study a disease.
Karl Herrup is Professor of Neurobiology and an Investigator in the Alzheimers Disease Research Center at the University of Pittsburgh School of Medicine. He is the author of How Not to Study a Disease: The Story of Alzheimers, from which this article is adapted.
Go here to read the rest:
The Powerful Case for Redefining Alzheimer's Disease - The MIT Press Reader
- Tango Parkinson's Therapy (Washington U. in St. Louis) - May 7th, 2011 [May 7th, 2011]
- Parkinson's Disease Treatment-Exercise Program-Part 2 of 4 - May 14th, 2011 [May 14th, 2011]
- Parkinson's Disease Stem Cell Treatment - Part 2 - May 21st, 2011 [May 21st, 2011]
- Deep Brain Stimulation treatment for Parkinson's disease - May 22nd, 2011 [May 22nd, 2011]
- Parkinson's Disease Treatment-Exercise Program-Part 4 of 4 - May 24th, 2011 [May 24th, 2011]
- James, Parkinson's disease, after stem cell treatment at Tiantan Puhua Hospital Beijing - May 30th, 2011 [May 30th, 2011]
- Parkinson's Disease Stem Cell Treatment - Part 1 - May 30th, 2011 [May 30th, 2011]
- Parkinson's Disease Treatment -- Mayo Clinic - June 2nd, 2011 [June 2nd, 2011]
- When should I start treatment if I have Parkinson's Disease? - June 3rd, 2011 [June 3rd, 2011]
- parkinson-treatment-with-cupping-4.flv - June 3rd, 2011 [June 3rd, 2011]
- New treatment options for Parkinson's Disease feat. Nashville Predators coach Brent Peterson - June 8th, 2011 [June 8th, 2011]
- Speech Treatment in Parkinson disease: Sharon Kha's Story - June 8th, 2011 [June 8th, 2011]
- How you can help cure Parkinson's - June 9th, 2011 [June 9th, 2011]
- TV9 - LADIES CLUB : "PARKINSON DISEASE" - CAUSE, SYMPTOMS - June 9th, 2011 [June 9th, 2011]
- Parkinson's Treatment: Case #1 - June 12th, 2011 [June 12th, 2011]
- parkinsons cure - June 17th, 2011 [June 17th, 2011]
- A Parkinson Patient Finds their Miracle. FCR Treatment helps Parkinson's Disease. - July 3rd, 2011 [July 3rd, 2011]
- Parkinson's Treatment: Case #2 - July 15th, 2011 [July 15th, 2011]
- TMJ Treatment Helping with Parkinson's Symptoms Dr. Gary Demerjian Burbank, California - July 15th, 2011 [July 15th, 2011]
- Parkinson's Treatment at Ta'ir Laser Center testimonial - July 16th, 2011 [July 16th, 2011]
- Parkinson's Disease client pre and post treatment - July 17th, 2011 [July 17th, 2011]
- Parkinson's Disease: Diagnosis, Causes and Treatment. Part 2 - July 18th, 2011 [July 18th, 2011]
- Parkinson's Disease: Diagnosis, Causes and Treatment part4 - July 18th, 2011 [July 18th, 2011]
- Glutathione for Parkinson's Disease. Learn why it helps symtoms - July 18th, 2011 [July 18th, 2011]
- Parkinson's Disease: Diagnosis, Causes and Treatment. - July 19th, 2011 [July 19th, 2011]
- parkinson-treatment-with-cupping-1.flv - July 20th, 2011 [July 20th, 2011]
- 7.30 - a treatment for Parkinson's Disease can cause problem gambling - July 27th, 2011 [July 27th, 2011]
- Parkinson's Disease Symptoms Improve with Non-Surgical TMJ Treatment: Dr. Gary Demerjian - July 29th, 2011 [July 29th, 2011]
- Werth Parkinson Centre, Daniella - Treatment - August 4th, 2011 [August 4th, 2011]
- 6.30 - Parkinson's treatment - August 19th, 2011 [August 19th, 2011]
- MDTV: New Drug Treatments for Parkinson's Disease - September 10th, 2011 [September 10th, 2011]
- Pakistan Parkinson's Disease patient Treatment, in chennai Surgery hospital - DINAMALAR - September 23rd, 2011 [September 23rd, 2011]
- Parkinson's treatment gives life back - October 2nd, 2011 [October 2nd, 2011]
- Parkinson Doctor Sarasota Discusses Parkinson's Disease Treatments - Video - October 15th, 2011 [October 15th, 2011]
- New treatments for Parkinson's disease - pt 1 - Video - October 16th, 2011 [October 16th, 2011]
- Parkinson's Disease Treatment - Year and a Half Later... - Video - October 19th, 2011 [October 19th, 2011]
- Still Life: The Search for a Parkinson's Cure - Video - October 22nd, 2011 [October 22nd, 2011]
- Can Exercise Treat Parkinson's? - Video - October 30th, 2011 [October 30th, 2011]
- Parkinsons Treatments | Symptoms Parkinsons - Video - November 2nd, 2011 [November 2nd, 2011]
- Symptoms - November 3rd, 2011 [November 3rd, 2011]
- Revolutionary Treatment for Parkinson's - Video - November 4th, 2011 [November 4th, 2011]
- Herbal Treatment for Parkinsons disease and recovery - Video - November 7th, 2011 [November 7th, 2011]
- Early Diagnosis and Treatment of Parkinson's Disease - Video - November 10th, 2011 [November 10th, 2011]
- Parkinson's Disease Treatment (part 1 of 4) at Penn Medicine - Video - November 15th, 2011 [November 15th, 2011]
- Parkinson's Disease Treatment - Video - November 18th, 2011 [November 18th, 2011]
- MDTV: Parkinson's Disease: Treating Off Times - Video - November 20th, 2011 [November 20th, 2011]
- parkinson-treatment-with-hijamah-therapy.3gp - Video - November 24th, 2011 [November 24th, 2011]
- parkinson-treatment-with-cupping-2.flv - Video - December 3rd, 2011 [December 3rd, 2011]
- Parkinsons Antioxident treatment before with Dr. Offutt.MOV - Video - December 7th, 2011 [December 7th, 2011]
- Teva Presenting Data on MS and Parkinson's Disease Treatments - Video - December 7th, 2011 [December 7th, 2011]
- LSVT® LOUD Treatment Benefits Parkinson's Disease Patient -- Hendricks Regional Health - Video - December 14th, 2011 [December 14th, 2011]
- Parkinson's Cure - Dating - Video - December 21st, 2011 [December 21st, 2011]
- Parkinson's Treatment part-2 - Video - December 29th, 2011 [December 29th, 2011]
- Parkinson's Treatment - Video - January 1st, 2012 [January 1st, 2012]
- Parkinson's Treatment - Deep Brain Stimulation - Video - January 2nd, 2012 [January 2nd, 2012]
- Parkinson's cure with out medicine - Video - January 10th, 2012 [January 10th, 2012]
- Parkinson's Disease and The Argentine Tango - Video - January 11th, 2012 [January 11th, 2012]
- Parkinson treatment shows positive results in clinical testing - Video - January 15th, 2012 [January 15th, 2012]
- Parkinson's Disease Treatment - Patient Testimony "Lad" - Video - January 27th, 2012 [January 27th, 2012]
- Parkinson - Video - January 27th, 2012 [January 27th, 2012]
- parkinson-treatment-with-cupping-3.flv - Video - January 28th, 2012 [January 28th, 2012]
- Parkinson's Disease: Balance, Gait (Walk) and Tremors Improve with New Non-Surgical Treatment Part 2 - Video - January 29th, 2012 [January 29th, 2012]
- Researchers visualize the development of Parkinson's cells - January 31st, 2012 [January 31st, 2012]
- NPH diagnosis in San Tan Valley man returns him to normal life - January 31st, 2012 [January 31st, 2012]
- Laser targeting could help fight Parkinson's - February 1st, 2012 [February 1st, 2012]
- Study of live human neurons reveals Parkinson's origins - February 7th, 2012 [February 7th, 2012]
- Lauren Sciences LLC awarded MJFF grant to develop a V-SmartTM therapeutic for Parkinson's disease - February 7th, 2012 [February 7th, 2012]
- "Biochemistry", Advances in Parkinson's Disease Treatment - Video - February 7th, 2012 [February 7th, 2012]
- Parkinson's Disease Symptoms Improve with Non-Surgical TMJ Treatment: Part 2 - Video - February 7th, 2012 [February 7th, 2012]
- Treatment of Parkinson's Disease Symptoms - Video - February 7th, 2012 [February 7th, 2012]
- Parkinson Disease - Surgical Treatment - Video - February 8th, 2012 [February 8th, 2012]
- MediGait Announces: GaitAid Device for Parkinson's Disease Shows Significant Step-initiation Improvement in New Trial ... - February 14th, 2012 [February 14th, 2012]
- Tai Chi Makes Parkinson’s Patients Steadier on Feet, Study Says - February 14th, 2012 [February 14th, 2012]
- Cleveland Clinic Joins 23andMe in the Search for Genetic Clues to Parkinson's Disease - February 14th, 2012 [February 14th, 2012]
- Cleveland Clinic to Recruit Parkinson's Patients for 23andMe - February 14th, 2012 [February 14th, 2012]
- Fairhope Parkinson's patient enters film in contest to awareness of disease - February 15th, 2012 [February 15th, 2012]
- Tai Chi may help Parkinson's patients regain balance - February 16th, 2012 [February 16th, 2012]
- Weight Training May Help Parkinson's Patients Retain Function - February 17th, 2012 [February 17th, 2012]
- Parkinson's Disease and Exercise: How Much Is Beneficial? - February 17th, 2012 [February 17th, 2012]
- Study shows exercise may help Parkinson's patients - February 17th, 2012 [February 17th, 2012]